Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Anti-CD19-CD20 CAR T cells |
| Trade Name | |
| Synonyms | |
| Drug Descriptions |
Anti-CD19-CD20 CAR T-cells are T-cells that are engineered to express a bispecific antibody that targets CD19 and CD20, which potentially results in an anti-tumor immune response against cells expressing either CD19 or CD20 (PMID: 27059623, PMID: 29207878). |
| DrugClasses | CD19 Immune Cell Therapy 72 CD20 Immune Cell Therapy 14 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Anti-CD19-CD20 CAR T cells | Anti-CD19-CD20 CAR T cells | 0 | 4 |
| Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine | Anti-CD19-CD20 CAR T cells Cyclophosphamide Fludarabine | 0 | 1 |